Analysis of the impact of the SARS-CoV-2 infection on the pediatric population hospitalized during the pandemic in the Greater Paris University Hospitals.

MIS-C multisystem inflammatory syndrome in children PIMS SARS-CoV-2 children data warehouse hospitalized child

Journal

Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492

Informations de publication

Date de publication:
2023
Historique:
received: 14 09 2022
accepted: 31 01 2023
entrez: 16 3 2023
pubmed: 17 3 2023
medline: 17 3 2023
Statut: epublish

Résumé

The clinical characteristics, disease progression and outcome in children affected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection appear significantly milder compared to older individuals. Nevertheless, the trends in hospitalization and clinical characteristics in the pediatric population seem to be different over time across the different epidemic waves. Our aim was to understand the impact of the different COVID-19 variants in the pediatric population hospitalized in the Pediatric Departments of the Public Hospital in the Greater Paris area by the analysis performed with the Assistance Publique-Hopitaux de Paris (AP-HP) Health Data Warehouse. This is a retrospective cohort study including 9,163 patients under 18 years of age, hospitalized from 1 March 2020 to 22 March 2022, in the Paris area, with confirmed infection by SARS-CoV-2. Three mutually exclusive groups with decreasing severity (Pediatric Inflammatory Multisystem Syndrome (PIMS), symptomatic infection, mild or asymptomatic infection) were defined and described regarding demography, medical history, complication of the SARS-CoV-2 infection, and treatment during admission. Temporal evolution was described by defining three successive waves (March-September 2020, October 2020-October 2021, and November 2021-March 2022) corresponding to the emergence of the successive variants. In the study period, 9,163 pediatric patients with SARS-CoV-2 infection were hospitalized in 21 AP-HP hospitals. The number of patients with SARS-CoV-2 infection increased over time for each wave of the pandemic (the mean number of patients per month during the first wave was 332, 322 during the 2nd, and 595 during the third wave). In the medical history, the most associated concomitant disease was chronic respiratory disease. Patients hospitalized during the third wave presented a higher incidence of pulmonary involvement (10.2% compared to 7% and 6.5% during the first and second waves, respectively). The highest incidence of PIMS was observed during the first and second waves (4.2% in the first and second waves compared to 2.3% in the 3rd wave). This analysis highlighted the high incidence of hospitalized children in the Greater Paris Area during the third wave of SARS-CoV-2 pandemic corresponding to the Omicron Covid-19 variant, which is probably an expression of a concomitant SARS-CoV-2, while a decreased incidence of PIMS complication was observed during the same period.

Sections du résumé

Background UNASSIGNED
The clinical characteristics, disease progression and outcome in children affected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection appear significantly milder compared to older individuals. Nevertheless, the trends in hospitalization and clinical characteristics in the pediatric population seem to be different over time across the different epidemic waves.
Objective UNASSIGNED
Our aim was to understand the impact of the different COVID-19 variants in the pediatric population hospitalized in the Pediatric Departments of the Public Hospital in the Greater Paris area by the analysis performed with the Assistance Publique-Hopitaux de Paris (AP-HP) Health Data Warehouse.
Methods UNASSIGNED
This is a retrospective cohort study including 9,163 patients under 18 years of age, hospitalized from 1 March 2020 to 22 March 2022, in the Paris area, with confirmed infection by SARS-CoV-2. Three mutually exclusive groups with decreasing severity (Pediatric Inflammatory Multisystem Syndrome (PIMS), symptomatic infection, mild or asymptomatic infection) were defined and described regarding demography, medical history, complication of the SARS-CoV-2 infection, and treatment during admission. Temporal evolution was described by defining three successive waves (March-September 2020, October 2020-October 2021, and November 2021-March 2022) corresponding to the emergence of the successive variants.
Results UNASSIGNED
In the study period, 9,163 pediatric patients with SARS-CoV-2 infection were hospitalized in 21 AP-HP hospitals. The number of patients with SARS-CoV-2 infection increased over time for each wave of the pandemic (the mean number of patients per month during the first wave was 332, 322 during the 2nd, and 595 during the third wave). In the medical history, the most associated concomitant disease was chronic respiratory disease. Patients hospitalized during the third wave presented a higher incidence of pulmonary involvement (10.2% compared to 7% and 6.5% during the first and second waves, respectively). The highest incidence of PIMS was observed during the first and second waves (4.2% in the first and second waves compared to 2.3% in the 3rd wave).
Discussion UNASSIGNED
This analysis highlighted the high incidence of hospitalized children in the Greater Paris Area during the third wave of SARS-CoV-2 pandemic corresponding to the Omicron Covid-19 variant, which is probably an expression of a concomitant SARS-CoV-2, while a decreased incidence of PIMS complication was observed during the same period.

Identifiants

pubmed: 36923274
doi: 10.3389/fped.2023.1044352
pmc: PMC10009109
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1044352

Informations de copyright

© 2023 Semeraro, Pinson, Populaire, Dellagi, Oualha, Beeker and Chappuy.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Lancet Child Adolesc Health. 2020 Sep;4(9):669-677
pubmed: 32653054
Nat Commun. 2022 Aug 3;13(1):4500
pubmed: 35922409
MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):422-426
pubmed: 32271728
Lancet Reg Health West Pac. 2022 Oct 07;27:100604
pubmed: 36237982
Curr Infect Dis Rep. 2022;24(4):51-62
pubmed: 35431658
Clin Infect Dis. 2023 Feb 8;76(3):e518-e521
pubmed: 35788276
Front Microbiol. 2022 Jun 13;13:902476
pubmed: 35770154
Front Pediatr. 2021 Oct 26;9:745364
pubmed: 34765576
Infection. 2022 Sep 1;:
pubmed: 36048361
JAMA. 2020 Jul 21;324(3):259-269
pubmed: 32511692
MMWR Morb Mortal Wkly Rep. 2022 Mar 25;71(12):466-473
pubmed: 35324880
Lancet Child Adolesc Health. 2021 Feb;5(2):133-141
pubmed: 32956615
Lancet Reg Health Eur. 2021 Apr;3:100075
pubmed: 34027512
Lancet Infect Dis. 2020 Jun;20(6):633-634
pubmed: 32220651
PLoS Med. 2015 Oct 06;12(10):e1001885
pubmed: 26440803
J Pak Med Assoc. 2022 Feb;72(2):305-311
pubmed: 35320183
Pediatrics. 2022 Sep 1;150(3):
pubmed: 35716376
Lancet Infect Dis. 2020 Nov;20(11):e276-e288
pubmed: 32818434
JAMA Netw Open. 2021 Jun 1;4(6):e2116420
pubmed: 34110391
J Pediatric Infect Dis Soc. 2022 Oct 25;11(10):440-447
pubmed: 35924454
Clin Microbiol Infect. 2022 Jun;28(6):897-899
pubmed: 35182762
JAMA Pediatr. 2022 Aug 1;176(8):821-823
pubmed: 35675054

Auteurs

Michaela Semeraro (M)

Centre D'Investigation Clinique-Unité de Recherche Clinique, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France.
EA7323 Pediatric and Perinatal Drug Evaluation and Pharmacology, Université Paris Cité, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.

Pierre Pinson (P)

EA7323 Pediatric and Perinatal Drug Evaluation and Pharmacology, Université Paris Cité, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Unité de Recherche Clinique, Hôpital Cochin, Paris, France.

Margaux Populaire (M)

Centre D'Investigation Clinique-Unité de Recherche Clinique, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France.

Mourad Dellagi (M)

EA7323 Pediatric and Perinatal Drug Evaluation and Pharmacology, Université Paris Cité, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Unité de Recherche Clinique, Hôpital Cochin, Paris, France.

Mehdi Oualha (M)

EA7323 Pediatric and Perinatal Drug Evaluation and Pharmacology, Université Paris Cité, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Unité de Recherche Clinique, Hôpital Cochin, Paris, France.
Pediatric Intensive Care Unit, Necker-Enfants-Malades University Hospital, Assistance Publique-Hôpitaux de Paris, Paris University, EA7323, Paris, France.

Nathanael Beeker (N)

EA7323 Pediatric and Perinatal Drug Evaluation and Pharmacology, Université Paris Cité, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Unité de Recherche Clinique, Hôpital Cochin, Paris, France.

Hélène Chappuy (H)

EA7323 Pediatric and Perinatal Drug Evaluation and Pharmacology, Université Paris Cité, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Unité de Recherche Clinique, Hôpital Cochin, Paris, France.
Pediatric Intensive Care Unit, Necker-Enfants-Malades University Hospital, Assistance Publique-Hôpitaux de Paris, Paris University, EA7323, Paris, France.
Service D'Urgences Pédiatriques, Hôpital Necker - Enfants Malades, Groupe Hospitalier AP-HP.Centre, EA7323, Université Paris Cité, Paris, France.

Classifications MeSH